NovoCure Ltd (NVCR):企業の製品パイプライン分析

◆英語タイトル:NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME36072PD
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD1,500 ⇒換算¥201,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥301,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NovoCure Ltd (NovoCure) develops and commercializes novel delivery systems for the treatment of cancers of brain, abdomen, and torso. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division solid tumor cancer cells. The company markets TTF-based delivery systems: NovoTTF-100L for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both of its marketed products are indicated in combination with standard chemotherapies. NovoCure is also advancing product development and clinical programs intended to improve the survival of patients with brain metastases, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company NovoCure Ltd
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
NovoCure Ltd Company Overview
NovoCure Ltd Company Snapshot
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd – Pipeline Analysis Overview
Business Description
NovoCure Ltd – Key Facts
NovoCure Ltd – Major Products and Services
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
MAXPOINT Treatment Planning Software
MAXPOINT Treatment Planning Software Product Overview
NovoTTF-200A – Small Cell Lung Cancer
NovoTTF-200A – Small Cell Lung Cancer Product Overview
Optune – Brain Metastasis
Optune – Brain Metastasis Product Overview
Optune – Brain Metastasis Clinical Trial
Optune – Breast Cancer
Optune – Breast Cancer Product Overview
Optune – Cervical Cancer
Optune – Cervical Cancer Product Overview
Optune – Colorectal Carcinoma
Optune – Colorectal Carcinoma Product Overview
Optune – Ependymoma
Optune – Ependymoma Product Overview
Optune – Gastric Adenocarcinoma
Optune – Gastric Adenocarcinoma Product Overview
Optune – Gastric Adenocarcinoma Clinical Trial
Optune – Gliosarcoma
Optune – Gliosarcoma Product Overview
Optune – Liver Cancer
Optune – Liver Cancer Product Overview
Optune – Malignant Melanoma
Optune – Malignant Melanoma Product Overview
Optune – Medulloblastoma
Optune – Medulloblastoma Product Overview
Optune – Meningioma
Optune – Meningioma Product Overview
Optune – Mesothelioma
Optune – Mesothelioma Product Overview
Optune – Non – Small Cell Lung Cancer
Optune – Non – Small Cell Lung Cancer Product Overview
Optune – Non – Small Cell Lung Cancer Clinical Trial
Optune – Ovarian Cancer
Optune – Ovarian Cancer Product Overview
Optune – Ovarian Cancer Clinical Trial
Optune – Pancreatic Cancer
Optune – Pancreatic Cancer Product Overview
Optune – Pancreatic Cancer Clinical Trial
Optune – Pediatric Glioma
Optune – Pediatric Glioma Product Overview
Optune – Pediatric Glioma Clinical Trial
Optune – Renal Adenocarcinoma
Optune – Renal Adenocarcinoma Product Overview
Optune – Small Cell Lung Cancer
Optune – Small Cell Lung Cancer Product Overview
Optune – Urinary Transitional Cell Carcinoma
Optune – Urinary Transitional Cell Carcinoma Product Overview
Optune Plus Bevacizumab – Recurrent Glioblastoma
Optune Plus Bevacizumab – Recurrent Glioblastoma Product Overview
Optune Plus Bevacizumab – Recurrent Glioblastoma Clinical Trial
Optune With Marizomib And Temozolomide – Glioblastoma
Optune With Marizomib And Temozolomide – Glioblastoma Product Overview
Optune With Marizomib And Temozolomide – Glioblastoma Clinical Trial
NovoCure Ltd – Key Competitors
NovoCure Ltd – Key Employees
NovoCure Ltd – Key Employee Biographies
NovoCure Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
NovoCure Ltd, Recent Developments
Nov 10, 2020: Novocure announces agenda for Virtual Research and Development Day
Oct 29, 2020: Novocure announces strategic alliance with NYU Grossman School of Medicine for preclinical and clinical Research
Jul 28, 2020: Novocure announces recipients of 2nd Annual AACR-Novocure grants for tumor treating fields research program
Mar 12, 2020: Preclinical data show tumor treating fields induces immunogenic cell death resulting in enhanced antitumor efficacy when combined with Anti-PD-1 therapy
Feb 27, 2020: Novocure reports fourth quarter and full year 2019 financial results and provides company update
Feb 11, 2020: Mesothelioma treatment center offers new at-home device
Jan 21, 2020: Novocure announces national reimbursement in Israel for Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma
Jan 13, 2020: Novocure announces fourth quarter and full year 2019 preliminary net revenues and provides company update
Jan 09, 2020: Zai Lab and Novocure announce first patient enrolled in a phase 2 pilot trial of tumor treating fields together with chemotherapy as first-line treatment of gastric cancer
Oct 31, 2019: Novocure reports third quarter 2019 financial results and provides company update
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Indication
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd, Key Facts
NovoCure Ltd, Major Products and Services
NovoCure Ltd Number of Pipeline Products by Development Stage
NovoCure Ltd Pipeline Products Summary by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Ongoing Clinical Trials Summary
MAXPOINT Treatment Planning Software - Product Status
MAXPOINT Treatment Planning Software - Product Description
NovoTTF-200A - Small Cell Lung Cancer - Product Status
NovoTTF-200A - Small Cell Lung Cancer - Product Description
Optune - Brain Metastasis - Product Status
Optune - Brain Metastasis - Product Description
Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment
Optune - Brain Metastasis - Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma with Brain Metastasis
Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Optune - Brain Metastasis - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Optune - Breast Cancer - Product Status
Optune - Breast Cancer - Product Description
Optune - Cervical Cancer - Product Status
Optune - Cervical Cancer - Product Description
Optune - Colorectal Carcinoma - Product Status
Optune - Colorectal Carcinoma - Product Description
Optune - Ependymoma - Product Status
Optune - Ependymoma - Product Description
Optune - Gastric Adenocarcinoma - Product Status
Optune - Gastric Adenocarcinoma - Product Description
Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
Optune - Gliosarcoma - Product Status
Optune - Gliosarcoma - Product Description
Optune - Liver Cancer - Product Status
Optune - Liver Cancer - Product Description
Optune - Malignant Melanoma - Product Status
Optune - Malignant Melanoma - Product Description
Optune - Medulloblastoma - Product Status
Optune - Medulloblastoma - Product Description
Optune - Meningioma - Product Status
Optune - Meningioma - Product Description
Optune - Mesothelioma - Product Status
Optune - Mesothelioma - Product Description
Optune - Non - Small Cell Lung Cancer - Product Status
Optune - Non - Small Cell Lung Cancer - Product Description
Optune - Non - Small Cell Lung Cancer - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
Optune - Non - Small Cell Lung Cancer - Study Evaluating the Safety and Efficacy of Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Subjects with Non-small Cell Lung Cancer
Optune - Ovarian Cancer - Product Status
Optune - Ovarian Cancer - Product Description
Optune - Ovarian Cancer - An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant with Weekly Paclitaxel for Recurrent Ovarian Carcinoma
Optune - Ovarian Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer: ENGOT-ov50 / GOG-3029 / INNOVATE-3
Optune - Pancreatic Cancer - Product Status
Optune - Pancreatic Cancer - Product Description
Optune - Pancreatic Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Optune - Pediatric Glioma - Product Status
Optune - Pediatric Glioma - Product Description
Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612)
Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma
Optune - Renal Adenocarcinoma - Product Status
Optune - Renal Adenocarcinoma - Product Description
Optune - Small Cell Lung Cancer - Product Status
Optune - Small Cell Lung Cancer - Product Description
Optune - Urinary Transitional Cell Carcinoma - Product Status
Optune - Urinary Transitional Cell Carcinoma - Product Description
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
Optune With Marizomib And Temozolomide - Glioblastoma - Phase 1B, Multicenter, Open-label Study of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed who Grade IV Malignant Glioma
NovoCure Ltd, Key Employees
NovoCure Ltd, Key Employee Biographies
NovoCure Ltd, Subsidiaries
Glossary

★海外企業調査レポート[NovoCure Ltd (NVCR):企業の製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Andrew Peller Limited:企業の戦略・SWOT・財務情報
    Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report Summary Andrew Peller Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Carmot Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Carmot Therapeutics Inc (Carmot Therapeutics) is a biotechnology company that discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. The company provides product portfolio such as encompasses investigational candidates in preclinical trials: peptide-sm …
  • KGHM Polska Miedz SA:企業の戦略・SWOT・財務情報
    KGHM Polska Miedz SA - Strategy, SWOT and Corporate Finance Report Summary KGHM Polska Miedz SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Spark Therapeutics Inc (ONCE):企業の財務・戦略的SWOT分析
    Summary Spark Therapeutics Inc (Spark) is a clinical-stage gene therapy company which provides gene therapies for inherited retinal diseases (IRDs), neurodegenerative diseases, as well as liver diseases. Its pipeline products include SPK-RPE65, SPK-CHM, rhonova, LHON, SPK-FIX, SPK-FVIII and SPK-TPP1 …
  • Mindray Medical International Limited:企業の戦略・SWOT・財務情報
    Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report Summary Mindray Medical International Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Mahaweli Reach Hotels Plc:企業の戦略・SWOT・財務分析
    Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary Mahaweli Reach Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Aeroports de Paris SA:戦略・SWOT・企業財務分析
    Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report Summary Aeroports de Paris SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Oxeia Biopharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxeia Biopharmaceuticals Inc (Oxeia Biopharmaceuticals) is a clinical stage biotech company that develops drug treatments for mild traumatic brain injury or concussion and underlying neuro-metabolic dysfunction. The company’s lead pipeline candidate includes OXE-103, potent mitochondrial sta …
  • Salk Institute for Biological Studies:製薬・医療:M&Aディール及び事業提携情報
    Summary Salk Institute for Biological Studies (Salk) is a research institute that offers biological research programs. The institute’s areas of research comprise aging and regenerative medicine, cancer biology, immune system biology, metabolism and diabetes, neuroscience and neurological disorders, …
  • Sunnybrook Research Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary Sunnybrook Research Institute (SRI) an educational institute that offers medical education and research services. The institute provides undergraduate, postgraduate and doctoral degree programs. It provides research platforms for biological sciences, evaluative clinical sciences and physical …
  • Portland General Electric Co (POR):企業の財務・戦略的SWOT分析
    Portland General Electric Co (POR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • SIGA Technologies Inc (SIGA):企業の財務・戦略的SWOT分析
    Summary SIGA Technologies Inc (SIGA) is a health security service provider. The company develops and commercialise solutions for serious unmet medical needs and bio threats. It offers antiviral drug to treat smallpox disease. SIGA offers product such as TPOXX. The company’s Tecovirimat is combined w …
  • Xtract Resources Plc (XTR):企業の財務・戦略的SWOT分析
    Summary Xtract Resources Plc (Xtract Resources), formerly Xtract Energy plc is a mining and mineral exploration and development company that offers mineral resources. The company acquires, explores, manages, operates, produces, mines, extracts, and develops gold and mineral resource deposit properti …
  • Yeda Research and Development Company Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Yeda Research and Development Company Ltd (Yeda), a subsidiary of Weizmann Institute of Science is a technology transfer company that provides research and science education. The company identifies and assesses research projects with commercial potential, protects the intellectual property o …
  • Capitol Health Ltd (CAJ):企業の財務・戦略的SWOT分析
    Summary Capitol Health Ltd (Capitol Health) is a diagnostic imaging service provider. The company offers services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic resonance imaging, mammography, nuclear medic …
  • M3 Biotechnology Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary M3 Biotechnology Inc (M3 Biotech) is a clinical stage biotech company that focuses on regenerative medicine. The company is developing clinical programs for the treatment of Alzheimer, MS, Parkinson and Alzheimerdisease (oral) among others. It utilizes discovery platform and develops small m …
  • T-System Inc:医療機器:M&Aディール及び事業提携情報
    Summary T-System Inc (T-System) is a provider of healthcare IT solutions with focus on emergency department documentation. T-System develops solutions for the episode-based care market, which includes emergency departments (EDs) in hospitals, freestanding emergency centers and urgent care centers. B …
  • SM Energy Company:企業の戦略・SWOT・財務情報
    SM Energy Company - Strategy, SWOT and Corporate Finance Report Summary SM Energy Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Duke Energy Carolinas LLC:発電所・企業SWOT分析
    Duke Energy Carolinas LLC – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • Cellect Biotechnology Ltd (APOP):製薬・医療:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆